{"id":185277,"date":"2025-12-02T08:25:00","date_gmt":"2025-12-02T07:25:00","guid":{"rendered":"https:\/\/www.ainia.com\/?p=185277"},"modified":"2025-12-02T08:27:02","modified_gmt":"2025-12-02T07:27:02","slug":"new-advances-in-discovering-and-targeting-natural-therapies-against-inflammatory-colon-diseases","status":"publish","type":"post","link":"https:\/\/www.ainia.com\/en\/ainia-news\/new-advances-in-discovering-and-targeting-natural-therapies-against-inflammatory-colon-diseases\/","title":{"rendered":"New advances in discovering and targeting natural therapies against inflammatory colon diseases"},"content":{"rendered":"

[vc_row][vc_column]In AINIA, we have developed new biotechnological tools and advanced<\/a> in vitro<\/em> models<\/a><\/strong> that enable us to identify molecules with therapeutic potential, enhance their extraction, and target them specifically to the colon<\/strong>. Thanks to technologies such as supercritical CO\u2082, 3D models, and controlled-release systems<\/strong>, we are now one step closer to new natural strategies for addressing inflammatory bowel diseases. In this article, we present in detail the most relevant results of this second yearly phase.<\/p>\n

Innovation for New Colon-Targeted Therapies<\/strong><\/h2>\n

Inflammatory bowel diseases and colorectal cancer continue to rise worldwide.<\/strong> Their impact on quality of life, together with the high associated healthcare costs, underscores the need to develop more effective and safer therapeutic solutions grounded in solid scientific evidence.<\/p>\n

In this context, PHARMANOVA II has built upon the work initiated during the first year, working closely with the Valencian companies N<\/strong>ova Terra Foods and Monteloeder to advance biotechnological and tissue-based tools capable of identifying, characterising, and directing new natural molecules toward key therapeutic targets in the colon.<\/p>\n

In this new phase, we have deepened our work in cellular screening tools, advanced in vitro<\/em> models, supercritical CO\u2082 fractionation technologies, and colon-targeted controlled-release systems.<\/strong> All with a clear purpose: to accelerate preclinical research and open new opportunities for the development of ingredients and compounds with therapeutic potential.<\/p>\n

In this video, we present a clear and visual overview of PHARMANOVA II milestones and advancements\u2014from screening platforms and organ-on-chip<\/em> models<\/strong> to extraction and controlled-release strategies developed in this new project stage. A dynamic synthesis of how we are moving towards new natural-compound-based solutions for inflammatory colon diseases.<\/p>\n

\u00a0<\/span>\u00a0<\/span><\/p>\n